Skip to main content

Table 4 CMR parameters of patients with MD2 and FSHD1 at baseline and at follow-up

From: Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study

Parameter

MD2

FSHD1

Baseline (n = 31)

Follow-up n = 22

p-value

Baseline n = 52

Follow-up

n = 41

p value

LVEF (%)

68 ± 6

62 ± 6

 < 0.01

63 ± 5

60 ± 3

0.762

LVEDV (ml)

126 ± 22

124 ± 29

0.605

128 ± 21

139 ± 34

0.131

LVEDVI (ml/cm)

0.80 ± 0.11

0.73 ± 0.15

0.275

0.70 ± 0.10

0.79 ± 0.17

 < 0.01

LV mass (g)

104 ± 27

92 ± 24

0.124

99 ± 25

102 ± 24

0.630

LV mass index (g/cm)

0.60 ± 0.14

0.54 ± 0.12

0.110

0.56 ± 0.13

0.57 ± 0.12

0.524

LV stroke volume (ml)

85 ± 13

78 ± 17

0.113

80 ± 15

84 ± 18

0.084

LV stroke volume index (ml/m2)

46 ± 6

42 ± 6

0.063

45 ± 8

48 ± 9

0.245

RVEF (%)

59 ± 7

54 ± 4

 < 0.01

51 ± 6

49 ± 5

0.104

RVEDV (ml)

140 ± 29

146 ± 33

0.444

160 ± 31

169 ± 28

0.470

RVEDVI (ml/m2)

76 ± 15

79 ± 14

0.456

83 ± 16

88 ± 14

0.422

RV stroke volume (ml)

82 ± 18

80 ± 19

0.932

76 ± 18

83 ± 18

0.082

RV stroke volume index (ml/m2)

44 ± 89

43 ± 8

0.852

40 ± 8

43 ± 8

0.063

LAEF (%)

60 ± 8

57 ± 7

0.392

62 ± 8

60 ± 7

0.452

LAEDV (ml)

63 ± 18

71 ± 25

0.275

54 ± 14

61 ± 14

0.021

LAEDVI(ml/m2)

35 ± 8

38 ± 25

0.288

28 ± 7

32 ± 8

0.027

LA (cm2)

21 ± 3

24 ± 5

 < 0.01

19 ± 3

22 ± 3

 < 0.01

RA (cm2)

21 ± 3

24 ± 5

0.040

20 ± 3

23 ± 4

0.029

Native T1 basal (ms)

1029 ± 30

1015 ± 38

p = 0.066

1010 ± 26

991 ± 24

 < 0.01

Native T1 mid (ms)

1012 ± 38

998 ± 30

p = 0.258

991 ± 39

989 ± 30

p = 0.102

Native T1 apical (ms)

1018 ± 50

999 ± 32

p = 0.163

983 ± 41

970 ± 40

p = 0.203

ECV basal (%)

26 ± 3

24 ± 3

 < 0.01

26 ± 3

22 ± 2

 < 0.01

ECV mid (%)

26 ± 2

24 ± 2

 < 0.01

26 ± 3

23 ± 3

 < 0.01

ECV apical (%)

29 ± 3

26 ± 2

 < 0.01

27 ± 3

24 ± 2

 < 0.01

T2 basal (ms)

51 ± 2

49 ± 2

 < 0.01

50 ± 4

47 ± 2

 < 0.01

T2 mid (ms)

52 ± 3

49 ± 3

 < 0.01

51 ± 3

47 ± 2

 < 0.01

T2 apical (ms)

55 ± 4

50 ± 2

 < 0.01

53 ± 3

48 ± 2

 < 0.01

Cell volume basal (ml)

72 ± 18

68 ± 17

p = 0.409

71 ± 19

74 ± 22

p = 0.308

Cell volume mid (ml)

70 ± 19

76 ± 17

p = 0.553

71 ± 20

73 ± 22

p = 0.361

Fibrosis volume basal (ml)

25 ± 9

20 ± 7

p = 0.055

24 ± 8

20 ± 7

p = 0.023

Fibrosis volume mid (ml)

26 ± 7

21 ± 6

 < 0.01

23 ± 7

22 ± 7

p = 0.032

GLS (%) LGE(-) patients

-17.9 ± 1

-16.8 ± 1

 < 0.01

-18.3 ± 1

-16.4 ± 1

p < 0.01

  1. Data are shown as mean values ± standard deviation (SD) according to the AHA-segment model. Significant differences (p < 0.05) are highlighted in bold
  2. BMI body mass index, BSA body surface area (Mosteller), HR heart rate, BP blood pressure, LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVEDVI eft ventricular end-diastolic volume index, LVESV left ventricular end-systolic volume, LA left atrium, RA right atrium, GLS global longitudinal strain, ECV extracellular volume fraction